Drugs / TTI-621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02890368 | Sep 2016 → Mar 2020 | breast carcinoma, cutaneous neuroendocrine carcinoma, melanoma, mycosis fungoides +2 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTI-621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02890368 ↗ |
| Action | Inhibit | “TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (antiphagocytic) signal to macrophages.” NCT02890368 ↗ |
| Modality | Protein / enzyme biologic | “TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein” NCT02890368 ↗ |
| Route | Other | “intratumoral injections” NCT02890368 ↗ |